Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

The value of tumor deposits in prognosis evaluation and clinical stage optimization of colorectal cancer: A real-world population-based retrospective cohort study.

Chang Wang, Yizhuo Wang, Jiaying Liang et al. Jun 01, 2026 pp. 3642-3642 10.1200/jco.2026.44.16_suppl.3642

3642 Background: The location and weight of tumor deposit (TD) in the TNM staging system may be seriously underestimated,...

Efficacy and safety of non-covalent BTK inhibitors: A systematic review focused on indolent lymphomas.

Shivam Rainchwar, Ashwini Khadatkar, Niraj More et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19081

e19081 Background: Covalent Bruton’s tyrosine kinase inhibitors (cBTKi) have transformed the treatment of B-cell malignanc...

Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) + pembrolizumab in patients (pts) with previously untreated locally advanced/metastatic urothelial carcinoma (la/mUC).

Yohann Loriot, Felipe Reyes-Cosmelli, Hernan Javier Cutuli et al. Jun 01, 2026 pp. 4516-4516 10.1200/jco.2026.44.16_suppl.4516

4516 Background: Zele is a highly selective Bicycle Drug Conjugate (BDC) targeting Nectin-4, a protein overexpressed in la...

Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

Marcelo Capra, Gurdeep Parmar, Fernanda Seguro et al. Jun 01, 2026 pp. 7564-7564 10.1200/jco.2026.44.16_suppl.7564

7564 Background: In combination with conventional doublet and triplet therapy, isatuximab (Isa) provides significant benef...

Beyond <i>ESR1</i> : Multi-pathway genomic drivers of endocrine resistance in HR⁺/HER2⁻ breast cancer.

Humaid Obaid Al-Shamsi, Massimo Cristofanilli, Muzammil Shaikh et al. Jun 01, 2026 pp. 1071-1071 10.1200/jco.2026.44.16_suppl.1071

1071 Background: Endocrine resistance in HR⁺/HER2⁻ breast cancer is often associated with acquisition of...

Phase I light-dose escalation study in locally advanced pancreatic ductal adenocarcinoma: Intra-arterial (IA) padeliporfin vascular-targeted photodynamic therapy (VTP).

Nadine Abi-Jaoudeh, Jennifer Brooke Valerin, Vincent Chung et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps4267

TPS4267 Background: Locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) with &gt; 180° vascular encasement of majo...

Real-world efficacy of nirogacestat compared to prior standard-of-care (SOC) systemic agents in desmoid tumors.

HeeKyung Kim, Warren Allen Chow Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23542

e23542 Background: Desmoid tumors are rare, locally aggressive fibroblastic neoplasms for which systemic therapy has histo...

Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.

Mark Agulnik, Jason K. Sicklick, Shreyaskumar Patel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps11589

TPS11589 Background: GIST is the most common mesenchymal neoplasm of the digestive tract and is mainly driven by gain-of-f...

Baseline dyslipidemia in treatment-naïve breast cancer: Molecular subtype–specific patterns in a large cohort.

Zechang Xin, Xiaoyu Zhu, Pisong Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12692

e12692 Background: Cardiovascular disease has emerged as a major cause of long-term morbidity and mortality among breast c...

Comparative real-world safety outcomes of Pola-R-CHP versus R-CHOP in high-grade diffuse large B-cell lymphoma (DLBCL): A TriNetX study.

Israr Khan, Fayaz Aijaz Ahmed Khan, Qamar Iqbal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19000

e19000 Background: The POLARIX trial established polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin...

Clinical associations of cannabis use among patients receiving immune checkpoint inhibitors: A real-world analysis.

Qiuchen Li, John Paul Khouzam, Fangzhou Liu et al. Jun 01, 2026 pp. 11143-11143 10.1200/jco.2026.44.16_suppl.11143

11143 Background: Cannabis use is common in patients with cancer, yet its clinical associations during immune checkpoint i...

Evaluation of long-term follow-up non-respondence in a prospective study of financial toxicity of patients after radiation therapy.

Hannah Koo, Daniela Reyes, Chaewon Hwang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23266

e23266 Background: Barriers to enrollment and retention of socioeconomically vulnerable patients limit the diversity and g...

Phase I/II study of liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas.

Matthias Holdhoff, Solmaz Sahebjam, Peng Huang et al. Jun 01, 2026 pp. 2069-2069 10.1200/jco.2026.44.16_suppl.2069

2069 Background: Liposomal curcumin (LC) is an intravenous formulation designed to enhance curcumin delivery and modulate...

Predictors of mechanical ventilation in metastatic cancer hospitalizations: A National Inpatient Sample study.

Davin Turku, Fiqe Khan, Siddharth Karipineni et al. Jun 01, 2026 pp. 11044-11044 10.1200/jco.2026.44.16_suppl.11044

11044 Background: Invasive mechanical ventilation (MV) represents a major escalation of supportive care in metastatic canc...

The impact of ketogenic diet and psychological factors on tumor shrinkage in breast cancer patients receiving neoadjuvant chemotherapy: A prospective clinical trial.

Mehmet Artaç, Senay Burcin Alkan, Bilgeşah Kılıçtaş et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23287

e23287 Background: The response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is influenced by metabolic and psy...

A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Charlene Mantia, Glenn J. Hanna, Yohann Loriot et al. Jun 01, 2026 pp. 6062-6062 10.1200/jco.2026.44.16_suppl.6062

6062 Background: CRB-701 is a next-generation Nectin-4–targeted monomethyl auristatin E (MMAE)-based antibody–drug conjuga...

Impact of chronic atrial fibrillation on outcomes of acute pulmonary embolism in pancreatic cancer patients.

Karansher Singh Randhawa, Sakshi Dixit, FNU Anamika et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16368

e16368 Background: Chronic atrial fibrillation increases thromboembolic risk and may worsen outcomes in acute pulmonary em...

Tumor-agnostic and cross-indication actionable alterations in <i>IDH</i> -wildtype glioma: Precision oncology opportunities in an aggressive disease.

Nitesh Rohatgi, Darshana Suresh Patil, Kunjahari Medhi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14060

e14060 Background: Gliomas have few approved targeted therapies. Given frequent blood-brain-barrier disruption in gliomas,...

Phase 2 study of intratumoral oncolytic VV1 plus cemiplimab: Simon's stage 1 results from head and neck squamous cell carcinoma (HNSCC) cohort.

Patrick Walsh McGarrah, Steven Francis Powell, Anna C. Nguyen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18026

e18026 Background: Immune checkpoint inhibitor (ICI) therapy is part of standard of care first-line therapy for recurrent...

OMAHA-004: Phase 3 trial of the steroidogenesis inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI.

Donald Charles Vile, Karim Olivier Fizazi, Zheng Hong Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5135

TPS5135 Background: Opevesostat (MK-5684; ODM-208) is an oral, nonsteroidal inhibitor of cytochrome P450 11A1 (CYP11A1), a...

Closing the depression gap in community oncology: Real-world outcomes from collaborative care.

Tyler Jones, Elizabeth Cleary, Cameron Schilling et al. Jun 01, 2026 pp. 12088-12088 10.1200/jco.2026.44.16_suppl.12088

12088 Background: Depression is prevalent among patients with cancer, yet access to evidence-based care remains uneven. Co...

Support of academic non-clinical efforts for cancer investigator faculty at Association of American Cancer Institutes.

Paula M. Fracasso, Thomas J. George, Hailey Honeycutt et al. Jun 01, 2026 pp. 9005-9005 10.1200/jco.2026.44.16_suppl.9005

9005 Background: Academic non-clinical time (NCT) for physician scientists (PS) and clinical investigators (CI) is critica...

Day-7 single-cell RNA sequencing of acute lung responses after 17-Gy whole-thorax irradiation in mice.

Qianqian Lei, Kegui Weng, Ye Hong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24193

e24193 Background: Radiation pneumonitis (RP) is a clinically important toxicity of thoracic radiotherapy and can set the...

Safety and feasibility of outpatient administration of targeted alpha therapies: A systematic review and meta-analysis of radiation exposure and waste management.

Haroon Alamy, Asatur Chakmanyan, Rakhshanda khan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23183

e23183 Background: Targeted alpha therapies offer potent antitumor efficacy but are traditionally administered in speciali...

Factors associated with delays in treatment initiation and interruptions in head and neck squamous cell carcinoma: A retrospective single-institution analysis.

Audrey Harris, Simran Chandra, Zain Al-Momani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18115

e18115 Background: Timely initiation and uninterrupted delivery of curative-intent therapy are critical in head and neck s...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page